Farther Finance Advisors’s Monte Rosa Therapeutics GLUE Stock Holding History

Farther Finance Advisors’s Portfolio GLUE Stock Details GLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$5.83K	Buy	489 +174	+55%	+$2.98K	﹤0.01%	4926
2026 Q2	$7.61K	Buy	315 +17	+6%	+$321	﹤0.01%	4589
2026 Q1	$5.12K	Sell	298 -141	-32%	-$2.7K	﹤0.01%	4480
2025 Q4	$6.88K	Buy	+439	New	+$5.92K	﹤0.01%	4148

Other funds holding GLUE

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Paladin Partners Hartland, Wisconsin $162M AUM 13.31% 1-Year Est. Return

Farther Finance Advisors's GLUE Position: Q3 2026 in Review

Farther Finance Advisors increased its Monte Rosa Therapeutics (GLUE) stake by 55% in Q3 2026, buying an estimated $2.98K and bringing the position to 489 shares worth $5.83K. The position accounts for ﹤0.01% of the portfolio, ranked #4926.

Farther Finance Advisors first reported a position in GLUE in Q4 2025 and has held it in 4 quarters since. The position peaked at $7.61K in Q2 2026. 3 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.

Farther Finance Advisors held 489 shares of Monte Rosa Therapeutics worth $5.83K as of Q3 2026.
Farther Finance Advisors bought 174 Monte Rosa Therapeutics shares in Q3 2026, an estimated $2.98K.
Monte Rosa Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #4926 holding.
Farther Finance Advisors first reported a position in Monte Rosa Therapeutics in Q4 2025 and has held it in 4 quarters since.
Farther Finance Advisors's Monte Rosa Therapeutics position peaked at $7.61K in Q2 2026.
3 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.